Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Philip J Mease¹, Rodrigo Luppino Assad², Shigeyoshi Tsuji³, Pascal Richette⁴, Arathi Setty⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁵, Sandra Ciecinski⁶ and Filip Van den bosch⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, ³Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁴Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Steven Feldman¹, Heimo stroissnig², Richard Kay³, Joanna Sobierska⁴, Roshan Dias⁴, Eric Guenzi⁵, Hendrik Otto², Halimuniyazi Haliduola², Abid Sattar⁶, Ruth Ruffieux⁴, Matjaz Steijger⁴ and Fausto Berti⁴, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²Alvotech, Jülich, Germany, ³RK Statistics, Bakewell, United Kingdom, ⁴Alvotech, Zürich, Switzerland, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, London, United Kingdom
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…
Abstract Number: 0768 • ACR Convergence 2022
Reevaluating Clinical Outcomes of Patients on Combination Biologics
Ryan Mathew¹, Alexa Meara², ChienWei Chiang³, Komal Paradakar³, Ambra Burrell³ and Gabriel Kirsch³, ¹The Ohio State University Medical Center, Skokie, IL, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Biologic treatments such as monoclonal antibodies have become first line treatment for many autoimmune diseases and now monoclonal antibodies are being used to treated…
Abstract Number: 1439 • ACR Convergence 2022
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Alan Smith¹, Pei-Ling Roerig¹, Jacob Cason², David Fancis², Brian Cooley², Mike Royal³, Vibeke Strand⁴, John Goldman⁵, Roel Querubin⁶ and Russell Ross², ¹4P Therapeutics, Peachtree Corners, GA, ²Sorrento Therapeutics, Atlanta, GA, ³Sorrento Therapeutics, San Diego, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Northside Hospital, Atlanta, GA, ⁶Atlanta Research Center for Rheumatology, Marietta, GA
Background/Purpose: The lymphatic system plays an integral role in the pathology of rheumatoid arthritis (RA)1 and mediates local RA flares2, yet most biologic therapies are…
Abstract Number: 2149 • ACR Convergence 2022
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Francisca Guimarães¹, Maria Pontes-Ferreira¹, Catarina Soares¹, Hugo Parente², Carolina Ochôa Matos³, Roberto Costa³, Daniela Oliveira⁴, Catarina Abreu⁵, Rafaela teixeira⁶, Sofia Ferreira Azevedo⁷, João Madruga-Dias⁸, Filipe Araújo⁹, Carla Campinho Ferreira¹⁰, Daniela Santos-Faria² and José Tavares-Costa², ¹Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ²Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal, ⁵Rheumatology Department, Hospital Garcia de Orta, Lisboa, Portugal, ⁶Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ⁹Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ¹⁰Rheumatology Department, Hospital de Braga, Braga, Portugal
Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…
Abstract Number: 0143 • ACR Convergence 2022
National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
José Luis Martín-Varillas¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, Alf Adán⁴, Inés Hernanz Rodríguez⁴, Emma Beltrán Catalán⁵, Sonia Castro Oreiro⁶, Patricia Fanlo⁷, Alvaro Garcia⁸, Ignacio Torre⁹, Miguel Cordero Coma¹⁰, Juan Ramón de Dios¹¹, A. Garcia-Aparicio¹², Marisa Hernandez Garfella¹³, Amalia Sánchez Andrade¹⁴, A. García-valle¹⁵, Olga Maiz¹⁶, Juan Roberto Miguelez Sanchez¹², Sergio Rodriguez Montero¹⁷, Ana Urruticoechea¹⁸, Raul Veroz¹⁹, Arantxa Conesa²⁰, Cristina Fernández-Carballido²¹, Vega Jovani Casano²², Olga Martinez²³, Patricia Moya Alvarado²⁴, Susana Romero Yuste²⁵, Paula Rubio Muñoz²⁶, eva Peña Sainz-Pardo²⁷, Marta Garijo Bufort²⁸, José Luis Hernández² and Ricardo Blanco²⁹, ¹Hospital de Laredo, Laredo, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴H. Clinic, Barcelona, Spain, ⁵Hospital del Mar, Barcelona, Spain, ⁶H. Universitario Joan XXIII, Barcelona, Spain, ⁷Complejo Hospitalario de Navarra, Navarra, Spain, ⁸Hospital Tajo, Madrid, Spain, ⁹Hospital de Basurto, Basurto, Spain, ¹⁰Hospital de León, León, Spain, ¹¹Hospital de Araba, Araba, Spain, ¹²Hospital Universitario de Toledo, Toledo, Spain, ¹³Hospital Universitario General de Valencia, València, Spain, ¹⁴Hospital Universitario Lucus Augusti, Lugo, Spain, ¹⁵Completo Asistencial Palencia, Palencia, Spain, ¹⁶Hospital Universitario de Donostia, San Sebastián, Spain, ¹⁷Virgen de Valme University Hospital, Sevilla, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹Hospital de Mérida, Mérida, Spain, ²⁰Hospital Universitario de Castellón, València, Spain, ²¹Agencia Valenciana de Salud, Alicante, Spain, ²²National Health system, Alicante, Spain, ²³Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²⁴Hospital Parc Tauli, Barcelona, Spain, ²⁵Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁶H. Esperit Sant, Barcelona, Spain, ²⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁸Hospital Sagunto, València, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of noninfectious uveitis. There are few reports on the effectiveness…
Abstract Number: 0778 • ACR Convergence 2022
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
Ulf Geisen¹, Ruben Rose², Dennis Berner³, Hayley Reid³, Jan Schirmer⁴, Florian Tran⁵, Sascha Gerdes⁶, Stefan Schreiber⁷, Andi Krumbholz¹, Petra Bacher⁷ and Bimba Hoyer¹, ¹UKSH Kiel, Kiel, Germany, ²Dep Infectiology UKSH Kiel, Kiel, Germany, ³Dep Rheumatology and clinical Immunology, UKSH Kiel, Kiel, Germany, ⁴University Medical Center Schleswig-Holstein, Kiel, Germany, ⁵Medical Department, UKSH Kiel, Kiel, Germany, ⁶Dermatology, UKSH Kiel, Kiel, Germany, ⁷Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
Background/Purpose: Background: The ongoing pandemic is an immunological challenge when using immune modulating drugs. The mRNA vaccines against SARS-CoV-2 are safe and efficient in most…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Federica Lumetti¹, Alarico Ariani², Camilla Coccolini³, Carlo Salvarani⁴ and Gilda Sandri⁴, ¹Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, ²Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, ³Università di Modena e Reggio Emilia, Modena, Italy, ⁴Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
Abstract Number: 0283 • ACR Convergence 2022
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Nobuyuki Yajima¹, Toshihiro Matsui² and Shigeto Tohma³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Carla Goncalves Schahin Saad¹, Matheus SR Silva², PERCIVAL SAMPAIO-BARROS¹, Julio Moraes³, Claudia G Schainberg², Celio Roberto goncalves¹, Andrea Shimabuco¹, Nadia Aikawa¹, Emily Figueiredo Neves Yuki¹, Sandra Gofinet Pasoto⁴, Leonard VK Kupa², Renato K Aoyama², Carlo Araujo¹, Clovis A. Silva⁵, ana Medeiros⁶ and Eloisa Silva Dutra de Oliveira Bonfa⁴, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, ³Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Jeffrey Curtis¹, Yujie Su², Cassie Clinton², Patrick Stewart³, Bryant England⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Bendcare, Boca Raton, FL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵FASTER, Hoover, AL
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
Abstract Number: 0287 • ACR Convergence 2022
Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Christina Charles-Schoeman¹, Roy Fleischmann², Stephen Hall³, Arthur Kavanaugh⁴, Andrea Rubbert-Roth⁵, Ryan DeMasi⁶, Sara Penn⁶, Andrew Garrison⁶, Samuel Anyanwu⁶, Radames Sierra-Zorita⁷ and Ricardo Xavier⁸, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴University of California San Diego, La Jolla, CA, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Puerto Rico, San Juan, Puerto Rico, ⁸Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…

« Previous Page
1
…
6
7
8
9
10
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].